4,4'-propylenebis(piperazine-2,6-dione)
4,4'-propylenebis(piperazine-2,6-dione) Basic information
- Product Name:
- 4,4'-propylenebis(piperazine-2,6-dione)
- Synonyms:
-
- 4,4'-propylenebis(piperazine-2,6-dione)
- 4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione)
- RAZOXANUM
- 4,4'-(1-Methylethylene)bis(2,6-piperazinedione)
- 4,4'-Propane-1,2-diyldipiperazine-2,6-dione
- Propyliminum
- 4-[3-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
- 4,4'-(Propane-1,2-diyl)
- CAS:
- 21416-67-1
- MF:
- C11H16N4O4
- MW:
- 268.27
- EINECS:
- 244-379-2
- Product Categories:
-
- Angiogenesis and metastasis.
- Mol File:
- 21416-67-1.mol
4,4'-propylenebis(piperazine-2,6-dione) Chemical Properties
- Melting point:
- 237-239°
- Boiling point:
- 411.43°C (rough estimate)
- Density
- 1.2576 (rough estimate)
- refractive index
- 1.6081 (estimate)
- storage temp.
- Inert atmosphere,2-8°C
- solubility
- DMSO: soluble40mg/mL
- form
- solid
- pka
- 11.00±0.20(Predicted)
- color
- White to off-white
- Water Solubility
- 3g/L(25 ºC)
4,4'-propylenebis(piperazine-2,6-dione) Usage And Synthesis
Uses
Razoxane is an inhibitor of Topo II.
Definition
ChEBI: Razoxane is a N-alkylpiperazine.
Biological Activity
Razoxane is clinically active against angiogenesis and metastasis. Razoxane specifically inhibits topoisomerase II without inducing DNA strand breaks (topo II catalytic inhibitor). It is an antimitotic agent with immunosuppressive properties. Razoxane inhibits blood-borne and lymphatic metastases in different experimental models. Studies have shown th at razoxane inhibits specifically the vasculogenic mimicry of B16F10 melanoma cells.
Safety Profile
Suspected human carcinogen producing leukemia and skin tumors. Moderately toxic by intraperitoneal route. Human effects: normocytic anemia and thrombocytopenia. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
in vivo
Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)[2].
| Animal Model: | Sprague-Dawley rats[2] |
| Dosage: | 30 mg/kg or 10 mg/kg per day |
| Administration: | Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation |
| Result: | Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor. |
IC 50
Topoisomerase II
4,4'-propylenebis(piperazine-2,6-dione) Supplier
- Tel
- 021-50182298 021-50180596
- sales@boylechem.com
- Tel
- 001-857-928-2050 or 1-888-588-9418
- sales@chemreagents.com
- Tel
- 0330-2528181
- sales@vdmbio.com
- Tel
- +86 21 61551611
- Tel
- 18-086626237 18086626237
- 2693528373@qq.com